NASDAQ:APGN

Apexigen (APGN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free APGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.39
▼
$0.39
50-Day Range: $0.36
▼
$0.44
52-Week Range: $0.33
▼
$8.28

Volume: N/A
Average Volume: 967,731 shs
Market Capitalization: $9.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Apexigen alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Apexigen Stock (NASDAQ:APGN)

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

APGN Stock News Headlines

September 7, 2023 | seekingalpha.com

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

August 11, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGN

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

June 3, 2023 | finance.yahoo.com

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 27, 2023 | msn.com

EF Hutton Reiterates Apexigen (APGN) Hold Recommendation

May 24, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGN

May 17, 2023 | msn.com

EF Hutton Maintains Apexigen (APGN) Buy Recommendation

May 16, 2023 | wsj.com

APG SGA S.A.

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 3, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?

March 3, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?

February 27, 2023 | finance.yahoo.com

Apexigen Announces Review of Strategic Alternatives and Restructuring

January 24, 2023 | finance.yahoo.com

Apexigen Announces Approximately $2.8 Million Private Placement Financing

January 23, 2023 | msn.com

Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket

January 19, 2023 | finance.yahoo.com

Apexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor Responses

January 19, 2023 | benzinga.com

Thinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?

January 19, 2023 | finance.yahoo.com

Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023

January 11, 2023 | benzinga.com

Apexigen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 140.5%

November 15, 2022 | finance.yahoo.com

Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update

November 11, 2022 | finance.yahoo.com

Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting

November 4, 2022 | bizjournals.com

How biotech companies are building drug pipelines with PIPEs

October 19, 2022 | msn.com

Wall Street Set to Open Lower as Higher-Than-Expected UK Inflation Rattles Investors

October 6, 2022 | ca.finance.yahoo.com

Apexigen, Inc. (APGN)

September 12, 2022 | finance.yahoo.com

Apexigen's Shares Fall After Data From Gastric Cancer Candidate

September 10, 2022 | finance.yahoo.com

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

September 7, 2022 | finance.yahoo.com

Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022 | finance.yahoo.com

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

See More Headlines

Receive APGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APGN
CUSIP: N/A
CIK: 1814140
Web: www.apexigen.com
Phone: 650-931-6236
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -614.82%
Return on Assets: -133.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.82
Quick Ratio: 0.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.09) per share
Price / Book: -4.28

Miscellaneous

Outstanding Shares: 24,862,000
Free Float: 20,088,000
Market Cap: $9.57 million
Optionable: Not Optionable
Beta: 3.60

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Xiaodong Yang M.D. (Age 62)
Ph.D., CEO & Director
Comp: $532.99k
Mr. Francis W. Sarena (Age 52)
Pres & COO
Comp: $474.19k
Dr. Frank J. Hsu M.D. (Age 62)
Chief Medical Officer
Comp: $520.92k
Mr. William E. Duke Jr. (Age 51)
Chief Financial Officer
Ms. Amy Wong (Age 57)
Sr. VP of Fin. & Operations
Dr. Jason Wright Ph.D.
Sr. VP of CMC

Key Competitors

View All Competitors

This page (NASDAQ:APGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Apexigen (APGN) Stock Price, News & Analysis

About Apexigen Stock (NASDAQ:APGN)

APGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info